📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial. (2019)

First Author: Smyth EC

Attributed to: CANCER: Trials with potential global reach and other challenging trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1001/jamaoncol.2019.1179

PubMed Identifier: 31219517

Publication URI: http://europepmc.org/abstract/MED/31219517

Type: Journal Article/Review

Volume: 5

Parent Publication: JAMA oncology

Issue: 8

ISSN: 2374-2437